A radiopharmaceutical contains a radioactive isotope that emits energy, which can be detected or used to provide an image (diagnostic agent) or is directly therapeutic within a diseased tissue. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.
Diagnostic radiopharmaceuticals are administered to a patient and enable physicians and researchers to non-invasively see the biochemical activity of cells, to diagnose or stage disease, identify which patients are best suited for a particular treatment, and help monitor a patient’s response to treatment. The imaging probes selectively locate at the site of disease, and release positrons or gamma rays that can be detected and digitally imaged with specialized cameras, producing images through positron emission tomography (PET) or single photon emission computed tomography (SPECT). The probes accumulate at the site of disease and the images appear as coloured or dark regions in partial or whole body structural images provided by computed tomography (CT) or magnetic resonance imaging (MRI). CPDC currently markets and distributes diagnostic radiopharmaceuticals and is providing next generation imaging probes for our partners’ clinical trials.
Therapeutic radiopharmaceuticals are administered to a patient to selectively seek out and deliver cell-killing radiation to the site of disease. These drugs are designed to bind selectively to specific biochemical protein receptors on or within cells at the site of the disease. Therapeutic radiopharmaceuticals can take many forms including highly selective proteins and antibodies, peptides or small molecules. The different types of molecules are designed to carry radioactive isotopes that release high energy beta or alpha particles, which cause damage to the target cell’s DNA resulting in cell death. New therapeutic radiopharmaceuticals are being designed to precisely target and kill cancer cells, while sparing normal healthy tissue, and clearing rapidly from blood and tissues. The CPDC develops therapeutic radiopharmaceuticals for cancer and supplies radiotherapeutics for our partners’ clinical trials.
Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.
Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.